Get the Stockscreener App
0.61
4.45%
0.026
Pre-market:
.61
Nexalin Technology Inc stock is traded at $0.61, with a volume of 290.46K.
It is up +4.45% in the last 24 hours and up +75.84% over the past month.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$0.584
Open:
$0.55
24h Volume:
290.46K
Relative Volume:
0.39
Market Cap:
$13.14M
Revenue:
$301.60K
Net Income/Loss:
$-8.22M
P/E Ratio:
-1.2067
EPS:
-0.5055
Net Cash Flow:
$-5.05M
1W Performance:
+61.50%
1M Performance:
+75.84%
6M Performance:
-43.52%
1Y Performance:
-48.74%
1-Day Range:
$0.54
$0.61
1-Week Range:
$0.37
$0.6262
52-Week Range:
$0.305
$2.00
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
0.61 | 12.58M | 301.60K | -8.22M | -5.05M | -0.5055 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc Stock (NXL) Latest News
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Acquires Digital Health Platform Ahead of FDA Pivotal Trial for Insomnia Treatment - Sleep Review
Nexalin Technology (NXL) Surges 16%: Breakout Potential Above ResistanceValue ETF - thelegaladvocate.com
Nexalin Technology earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
Nexalin Technology earnings beat, revenue fell short of estimates - Investing.com
Nexalin Technology, Inc.Common Stock (NQ: NXL - The Chronicle-Journal
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury - Sahm
Nexalin Technology (NXL) Surges 19% as Momentum Builds Toward Key ResistanceWave Equality - The Legal Advocate
Nexalin Technology (NXL) Q1 2026 Profit Slips to $-0.11 — Misses Analyst ForecastsFiscal Year Earnings - thelegaladvocate.com
House committee directs VA to research brain stimulation for TBI By Investing.com - Investing.com Australia
House committee directs VA to research brain stimulation for TBI - Investing.com
Maxim Group Maintains Nexalin Technology(NXL.US) With Buy Rating, Maintains Target Price $2 - Moomoo
Nexalin Technology Secures Key Neurostimulation Legislative - GlobeNewswire
Nexalin Technology (NXL) Q1 2026 Earnings Miss: EPS $-0.11 vs $-0.10 ExpectedSaaS Earnings Trends - thelegaladvocate.com
Nexalin Acquires PONM to Expand AI Health Platform - TipRanks
Nexalin Acquires PONM for $1.3 Million in Stock, Adds 24-Month GLV Collaboration - TradingView
Nexalin (NXL) acquires PONM AI health platform in $1.3M stock deal - Stock Titan
Nexalin acquires digital health platform PONM for $1.3M - Investing.com India
Nexalin acquires digital health platform PONM for $1.3M By Investing.com - Investing.com South Africa
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial - The Manila Times
Nexalin Acquires AI-Integrated Digital Health Platform - GlobeNewswire
Nexalin Technology, Inc. acquired PONM, Inc. from GreenLight Ventures, LLC for $1.3 million. - marketscreener.com
Nexalin Technology (NXL) Trading at $$0.34 — Key Decision Point 2026-05-14Popular Trader Picks - Newser
TradingKey - TradingKey
Number of shareholders of Nexalin Technology, Inc. – NASDAQ:NXL - TradingView
NXL Financials: Income Statement, Balance Sheet & Cash Flow | Nexalin Tech - Stock Titan
Nexalin Technology, Inc. 1Q 2026: Revenue $14.95K, EPS ($0.11) — 10-Q Summary - TradingView
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nexalin Technology (NXL) Q1 loss, cash burn and Nasdaq bid-price warning - Stock Titan
Peer-Reviewed Neuroimaging Data Supports Nexalin’s Technology for Chronic Insomnia - Sleep Review
Nexalin Technology Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
MSN Money - MSN
How Nexalin Technology (NXL) pricing offsets input costs | Q4 2025: EPS Misses EstimatesStrong Buy - Newser
NXL Stock Price, Quote & Chart | NEXALIN TECHNOLOGY INC (NASDAQ:NXL) - ChartMill
Nexalin reports sleep quality improvement in insomnia study By Investing.com - Investing.com South Africa
Nexalin reports sleep quality improvement in insomnia study - Investing.com
After 4 weeks, Nexalin insomnia study showed no sham-group sleep gain - Stock Titan
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia - GlobeNewswire
Nexalin Technology appoints Justin Fleet as CFO - MSN
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Quantisnow
Nexalin Technology appoints Justin Van Fleet as CFO - MSN
Nexalin Technology slides after pricing $5M stock offering - MSN
Nexalin announces pivotal insomnia trial, targets Q2 enrollment By Investing.com - Investing.com India
NXL Nexalin Technology Q4 2025 earnings narrowly miss consensus estimates, shares tick higher as investors overlook minor shortfall.Expert Entry Points - Xã Thanh Hà
Nexalin Advances Pivotal Insomnia Trial for HALO Clarity - The Globe and Mail
NXL (Nexalin Technology Inc.) reports narrow Q4 2025 EPS miss, shares rise 18 percent on positive investor sentiment.Binary Event - Cổng thông tin điện tử tỉnh Tây Ninh
Nexalin (NXL) funds 160-patient pivotal HALO Clarity insomnia trial - Stock Titan
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):